{"doi":"10.1080/15360288.2016.1210713","title":"Single- Versus Multiple-Drug Pharmacotherapy in the Management of Diabetic Painful Neuropathy","abstract":null,"journal":"Journal of Pain & Palliative Care Pharmacotherapy","year":2016,"id":650497,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":467596,"name":"Diana Brixner","orcid":"0000-0001-6637-6359","position":1,"is_corresponding":false},{"id":1696133,"name":"Arthur G. Lipman","orcid":null,"position":2,"is_corresponding":false},{"id":1350357,"name":"Michael Goodman","orcid":"0000-0001-6320-9707","position":3,"is_corresponding":false},{"id":692349,"name":"Man Hung","orcid":"0000-0003-2827-3740","position":4,"is_corresponding":false},{"id":1696140,"name":"Gary M. Oderda","orcid":null,"position":5,"is_corresponding":false},{"id":1696129,"name":"Kuan-Ling Kuo","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Single- Versus Multiple-Drug Pharmacotherapy in the Management of Diabetic Painful Neuropathy","abstract":"This study compared patient characteristics and health care costs between newly treated diabetic painful neuropathy (DPN) patients receiving mono- pharmacotherapy and those receiving combination pharmacotherapy. A retrospective cohort was developed through Inovalon's Medical Outcomes Research for Effectiveness and Economics Registry (MORE2) database. Patients included were ≥18 years on the date of first DPN prescription: tricyclic antidepressant, opioids, duloxetine, gabapentin, pregabalin, or lidocaine. The authors conducted a simple proportional hazards model comparing times to discontinuation, switch, or addon. Multiple logistic regression was used to identify predictors of combination pharmacotherapy. There were 7145 patients on mono-pharmacotherapy and 421 patients on combination pharmacotherapy. Patients receiving combination pharmacotherapy were 130% more likely to discontinue their medications than patients receiving mono-pharmacotherapy. Female patients and those with > 7 comorbidities were more likely to be started with combination pharmacotherapy. Elderly patients were less likely to be started with combination pharmacotherapy. The total cost of care difference between mono- and combination pharmacotherapy was not statistically significant (P = .66); therefore, newly treated DPN patients should add on another medication sooner than 30 days when considering combination pharmacotherapy. All first-line medications have similar efficacy; for this reason, cost should be considered in the treatment decision.","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"27541383","pmcid":null,"openalex_id":"https://openalex.org/W2510986948","authors":[],"funders":[],"total_grants":0,"fwci":0.187,"citation_percentile":0.5938589,"influential_citations":0,"citation_trend":[{"year":2016,"count":1},{"year":2021,"count":2},{"year":2025,"count":2}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.1080/15360288.2016.1210713","host_type":"publisher"},{"url":"https://doi.org/10.1080/15360288.2016.1210713","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/27541383","host_type":"repository"}],"fields_of_study":["Pain Mechanisms and Treatments","Botulinum Toxin and Related Neurological Disorders","Pharmacological Effects of Natural Compounds"],"mesh_terms":["Adolescent","Adult","Age Factors","Aged","Analgesics","Diabetic Neuropathies","Drug Therapy, Combination","Female","Humans","Male","Middle Aged","Retrospective Studies","Cohort Studies","Comorbidity","Logistic Models","Proportional Hazards Models","Health Care Costs","Young Adult"],"keywords":["Pharmacotherapy","Medicine","Pregabalin","Duloxetine","Combination therapy","Discontinuation","Retrospective cohort study","Internal medicine","Anesthesia","Costs","Diabetic","Neuropathy","Outcomes","Monotherapy","Painful","Patient Characteristics"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T05:35:18.725511Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}